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Abstract

The International Classification of Diseases (ICD) and the Diagnostic and Statistical Manual (DSM) are
routinely used in diagnosing illicit substance use disorders, but for people taking prescribed opioids they
remain controversial. In pain medicine, the concept of "Addiction" is preferred with reduced emphasis on
tolerance and withdrawal. This article examines the prevalence and characteristics of pharmaceutical opioid
dependence/disorder according to ICD, DSM, and the pain medicine concept of "Addiction," among chronic
noncancer pain (CNCP) patients prescribed opioids. In the current study, we used data from a national
sample of 1134 people prescribed opioids for CNCP. Past 12-month "Addiction" (based on Pain Medicine
definition), DSM, and ICD dependence definitions were assessed using the Composite International
Diagnostic Interview. Twenty-four percent of the cohort met the criteria for "Addiction," 18% for DSM-5 use
disorder and 19% for ICD-11 dependence. There was "substantial" concordance between "Addiction" and
both DSM-5 use disorder and ICD-11 dependence, although concordance was much greater with ICD-11
dependence (kappa = 0.63 and 0.79, respectively). Participants meeting the criteria for "Addiction" only were
older, less likely to engage in nonadherent behaviours, self-reported fewer problems or concerns with their
medication, and had lower rates of psychological distress than those who also met the DSM-5 and ICD-11
criteria. The definition of "Addiction" captures a larger group of patients than other classification systems and
includes people with fewer "risk" behaviours. Despite removal of tolerance and withdrawal for prescribed
opioid use for DSM-5, we found that "Addiction" was more closely related to an ICD-11 diagnosis of
pharmaceutical opioid dependence.
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Abstract
The International Classification of Diseases (ICD) and the Diagnostic and Statistical Manual (DSM) are
routinely used in diagnosing illicit substance use disorders, but for people taking prescribed opioids
they remain controversial. In pain medicine the concept of ‘Addiction’ is preferred with reduced
emphasis on tolerance and withdrawal. This paper examines the prevalence and characteristics of
pharmaceutical opioid dependence/disorder according to ICD, DSM and the pain medicine concept
of ‘Addiction’, among chronic non-cancer pain (CNCP) patients prescribed opioids. In the current
study we used data from a national sample of 1,134 people prescribed opioids for CNCP. Past 12
month ‘Addiction’ (based on Pain Medicine definition), DSM and ICD dependence definitions were
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assessed using the Composite International Diagnostic Interview.

Twenty-four percent of the cohort met criteria for ‘Addiction’, 18% for DSM-5 use disorder and 19%
for ICD-11 dependence. There was ‘substantial’ concordance between ‘Addiction’ and both DSM-5
use disorder and ICD-11 dependence, though concordance was much greater with ICD-11
dependence (kappa’s 0.63, 0.79, respectively). Participants meeting criteria for ‘Addiction’ only were
older, less likely to engage in non-adherent behaviours, self-reported fewer problems or concerns
with their medication, and had lower rates of psychological distress than those who also met DSM-5
and ICD-11 criteria.

The definition of ‘Addiction’ captures a larger group of patients than other classification systems, and
includes people with fewer ‘risk’ behaviours. Despite removal of tolerance and withdrawal for
prescribed opioid use for DSM-5, we found that ‘Addiction’ was more closely related to an ICD-11
diagnosis of pharmaceutical opioid dependence.

Introduction
There has been increasing concern about risks for problematic use of pharmaceutical opioids in
people prescribed opioids for chronic non-cancer pain (CNCP) [7]. Understanding the nature and
extent of this issue has been limited due to inconsistency in how problematic opioid use is defined
[28; 29; 36].

The International Classification of Diseases (ICD) and the Diagnostic and Statistical Manual (DSM) are
commonly used in illicit substance use research and clinical practice (See Appendix A for specific
operationalisations,

available

online

as

Supplemental

Digital

Content

at

http://links.lww.com/PAIN/A251). In the field of pain medicine, however, they remain controversial
[3; 29]; tolerance and withdrawal are considered normal physiological consequences of long-term
opioid use rather than indicators of problems. Other features are emphasised [21].

‘Addiction’, as defined by the American Academy of Pain Medicine, American Pain Society and
American Society of Addiction Medicine [28] is behaviour including one or more of the following,
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impaired control over drug use, compulsive use, continued use despite harm, and cravings. A recent
consensus statement from the Analgesic, Anaesthetic, and Addiction Clinical Trial Translations,
Innovations, Opportunities, and Networks (ACTTION) group [29] has supported and recommended
this definition in patients who have been prescribed medication for pain [25].

DSM-5 similarly specifies tolerance and withdrawal are not features of opioid use disorder in people
taking opioids “solely under medical supervision” [2].. In an earlier paper examining DSM vs ICD
definitions, DSM-% did not agree well with DSM-IV, ICD-10 or ICD-11 (preliminary criteria) [11]. ICD11 displayed the best model fit [11]. For a comparison of the features across the different
classification systems see Table 1.

Previous estimates of problematic opioid use in CNCP vary: 8-12% for ‘addiction’ [36], DSM-5 lifetime
pharmaceutical opioid use disorder ranged from 18.8% [11] to 41.3% [4] and lifetime ICD-11 opioid
dependence 9.9% [11]. However, assessment methods varied across studies, from examining clinical
notes to administering a structured, well-validated questionnaire.

There has been no contrast of ICD and DSM definitions and the pain medicine concept of ‘Addiction’
in a sample of patients prescribed opioids for CNCP. This paper uses data from a large, national,
community cohort of people prescribed opioids for CNCP, to examine:
1. The prevalence of people meeting criteria for the different definitions of opioid dependence
and use disorder (DSM and ICD), and ‘Addiction’
2. The degree of concordance between ‘Addiction’, DSM-IV, ICD-10 and ICD-11 ‘pharmaceutical
opioid dependence’, and the DSM-5 ‘opioid use disorder’;
3. The socio-demographic and clinical characteristics of persons meeting the different sets of
criteria for ‘Addiction’, DSM-5 and ICD-11; and
4. A comparison between those who meet criteria for ‘Addiction’ and those that do not meet
criteria for any problematic use (i.e. DSM-IV, ICD-10, ICD-11 dependence and DSM-5 use
disorder) and those who meet criteria for ‘Addiction’ only with those who meet criteria ICD11 dependence or criteria for DSM-5 pharmaceutical opioid use disorder.

Method
3

Study design and setting
The Pain and Opioid IN Treatment (POINT) study was designed to document patterns of
pharmaceutical opioid use, and risk of adverse events and outcomes, in a prospective cohort of
patients who were prescribed opioids for chronic non-cancer pain. The methodology of this cohort
has been described in detail elsewhere [6]. The study was approved by the Human Research Ethics
Committee of UNSW Australia (HREC reference: # HC12149). The current study is based on data
collected at the two-year time point. Included in the current paper is a sample of 1,134 participants
who had completed the two-year interview and had been prescribed opioids in the preceding 12
months.

Eligibility criteria
At study enrolment POINT participants were: 18 years or older; taking opioids for CNCP for more
than 6 weeks; competent in English; mentally and physically able to undertake telephone and selfcompletion interviews; without serious cognitive impairments; living with chronic non-cancer pain;
prescribed an opioid such as morphine, oxycodone or fentanyl (Schedule 8 in the Australian
classification of ‘drugs of dependence’ and subject to additional regulatory controls regarding
manufacture, supply, distribution, possession and use [32]. A history of injecting drug use was not an
exclusion criterion, but those currently prescribed pharmaceutical opioids for opioid substitution
therapy (OST) for heroin dependence or taking opioids for cancer pain were not eligible. Of the 2,091
participants assessed for eligibility, 90% (n=1873) were eligible and 1514 completed the baseline
interview (n=201 refused after being deemed eligible and 100 were unable to be contacted). We had
a completion rate of 82% (n=1,245) at the two-year time point; 113 participants have withdrawn over
the two-years, 45 have died and 111 participants had discontinued pharmaceutical opioid use 12
months or more prior to interview.

Phone interviews were conducted by trained interviewers who had received training in the computer
assisted personnel interviewing survey schedule. Interviewers had a minimum 3-year health or
psychology degree, were trained in how to respond to reports of suicidal thoughts or suicidal plans,
and were provided with glossaries of chronic pain medications and conditions.

The measures, tools, and domains collected were based on recommendations made under the
auspices of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials
4

(IMMPACT) [13; 33]. The six core domains identified as being important in measuring core outcomes
included pain, physical functioning, emotional functioning, participant ratings of improvement and
satisfaction with treatments, symptoms and adverse events and participant disposition. Full details of
the measures used in the study have been reported elsewhere [6].

Assessment of DSM and ICD dependence and pharmaceutical opioid use disorders and ‘Addiction’
Pharmaceutical opioid use disorders were assessed using the Composite International Diagnostic
Interview 3.0 (CIDI) [15]. The CIDI has been used widely in epidemiological studies in many countries
[12; 16; 26], and has been shown to have excellent inter-rater reliability [15], test–retest reliability
[15], and concordance with clinician diagnoses [14]. ‘Addiction’, and ICD and DSM diagnoses were
determined from the CIDI responses. ‘Addiction’ and the criteria and the numbers of patients
included in the various definitions are reported in Table 1 (see Appendix A for operationalisation of
criteria, available online as Supplemental Digital Content at http://links.lww.com/PAIN/A251).

For participants who used medications as prescribed (n=928), the criteria of tolerance and
withdrawal were not included for assessing fit with DSM-5 diagnoses. However, in those who
endorsed at least one aberrant behaviour, as collected in the Opioid Related Behaviours in Treatment
(ORBIT) scale, tolerance and withdrawal were included in assessing fit with DSM-5 opioid use
disorder (n=206). Aberrant behaviours included were injection, tampering, doctor shopping, or
diversion of opioids.

Pain and physical health measures
Current pain severity and pain interference were measured by the Brief Pain Inventory [8] as a
continuous score from zero to 10. Using the Pain Self-Efficacy Questionnaire [1], a cut-off of 30 was
used, as scores <30 have been shown to indicate less sustainable gains, and to predict a lower rate of
return to work and/or maintenance of treatment gains [9]. Participants were asked for how long they
had been in pain and from how many prescribers they had received their medication. Health service
utilisation was defined as ever having surgery for pain, having been in a pain management course, or
having seen a psychiatrist or psychologist.

The Short Form 12 (SF12) is a measure of general health functioning. It provides a physical and
mental health component core and there are population norms, with a mean score of 50 and a SD of
5

10. In the current study, we only used the physical dimension. A cut-off of two standard deviations
below the population mean was used to indicate severity in the current study.
Medications and problematic opioid use measures
Daily oral morphine equivalent (OME) doses for the pharmaceutical opioids taken by the cohort were
estimated following review and synthesis of a range of clinical guidelines [22]. Current average daily
dose (OME mgs/day) was calculated using opioid consumption from a one-week medication diary
completed as part of the 2-year interview. OME were calculated for the 1,035 participants that
reported past week opioid medication consumption.

The Prescribed Opioids Difficulty Scale (PODS) was used to measure participants' current problems
and concerns about using prescribed opioids [31]. We used a continuous score on both the problems
and the concerns domain on the PODS. The problems domain includes items such as “caused me to
have difficulty remembering”, “caused me to lose interest”, and “caused me to feel depressed”. The
concern domain includes items such as preoccupation with medication, needing a higher dose,
wanting to cut down, feeling dependent on medication and medication causing problems in work
and social settings alert [31].

The ORBIT is a 10-item measure of aberrant or non-adherent behaviours such as doctor shopping,
diversion and other examples of unsanctioned use of medications. Each item is scored between zero
to four to give a continuous score from 0-40 [19].

Mental health and substance use
Depression and generalized anxiety disorder were measured by the PHQ-9 and GAD-7 modules of the
Patient Health Questionnaire [17; 18]. Previously validated cut-offs were used as follows: moderate
to severe depression was defined as a score of ≥ 10 on the PHQ-9 [17] and moderate to severe
anxiety was defined as a score of ≥ 10 on the GAD-7 [30].
A score of ≥ 3 on the Primary Care PTSD screen (PC-PTSD) was used to indicate PTSD [23].
Participants were asked about lifetime and past 12 month alcohol and illicit drug use. Lifetime drug
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and alcohol use disorders (using ICD-10 dependence criteria) were assessed via the alcohol and drug
use module of the Composite International Diagnostic Interview (CIDI) [37].

The following questions on childhood maltreatment were asked, based on questions by Sansone [24]
: “Before the age of 16, did you experience sexual abuse, physical abuse, emotional abuse, physical
neglect, emotional and/or did you witness any violence." . In the current study only data from the
sexual, physical and emotional abuse questions were used and were combined into one dichotomous
variable of ‘any childhood abuse’.

Data analysis
Analyses used STATA, version 12.0 (Stata Corporation, College Station, TX, USA). We reported the
frequency of participants meeting each criterion for pharmaceutical opioid use disorder and
dependence according to the five classification systems.

We also examined the concordance

between numbers of participants meeting criteria for each definition of disorder and concordance
between each of the ‘Addiction’ criterion and the other diagnostic systems. Kappa, bias adjusted
kappa (BAK), sensitivity, specificity and positive and negative predictive values are reported [20] to
determine concordance between the ‘Addiction’ symptoms and the other classification systems.
Kappa interpretation was based those recommended by Viera and Garrett [35], these were; less than
0 less than chance agreement, 0.01-0.20 slight agreement, 0.21-0.40 fair agreement, 0.61-0.80
substantial agreement, 0.81-0.99 almost perfect agreement.

Proportions, means and standard deviations were reported. Where data were non-normally
distributed we reported median and inter-quartile range (IQR). Binary logistic regressions were used
to examine characteristics associated with concept of addiction compared to those that did not meet
criteria for any problematic use, according to traditional systems, and those that met criteria for
‘Addiction’ only, compared with ICD-11 dependence and DSM-5 use disorder. To understand the
characteristics of the participants who met criteria for ‘Addiction’ (n=271) we compared them with
those that did not meet criteria for any of the of the classification systems, including, DSM-IV, ICD-10,
ICD-11 dependence and DSM-5 used disorder (n=823). To understand characteristics of participants
captured under the concept of ‘Addiction’, that were not included in the traditional classification
systems of ICD-11 dependence and DSM-5 use disorder, we compared an ‘Addiction’ only group with

7

all who met criteria for DSM-5 (n=104 vs 202 respectively) and all who met criteria for ICD-11 (n=69
vs 213 respectively). Odds ratios and 95% Confidence Intervals are reported.

Results
Of the participants, 57% were female (95% CI 54-60), the median age was 60 (IQR 51-69), 43% were
unemployed (95%CI 40.0-46.2) and they had been prescribed opioids continuously for a median of 7
years (IQR 4-13). The most common pain conditions reported in the past 12 months were back and
neck problems (85%, 95%CI 82.8-87.5), followed by arthritis/rheumatism (76%, 95%CI 69.5-75.4) and
frequent headaches or migraines (33.1, 95%CI 30.0-36.3). The vast majority (87%, 95%CI 84.8-89.1)
reported the presence of more than one pain condition in the preceding 12 months.

Twenty-five percent of the sample met criteria for physical dependence (as defined by withdrawal),
and 13% met criteria for tolerance. Prevalence of problematic use differed depending on the
classification system used (Table 1). The prevalence of Dependence as defined by DSM-IV or ICD-10
was similar (8.4%, 95%CI 7.0-10.2 and 9.4%, 95%CI 7.8-11.2, respectively). Nineteen percent met
ICD-11 criteria for Dependence, 18% met criteria for DSM-5 use disorder, and 24% met criteria for
‘Addiction’. The relationship between ICD-11 and DSM-5 and ‘Addiction’ are presented in Figure 1.

Table 1 and figure 1 here

Measures of concordance between the diagnostic systems are presented in Table 2. There was
moderate concordance between ‘Addiction’ and DSM-IV, ICD-10 dependence (kappa 0.46 and 0.48,
respectively). There was substantial concordance between ‘Addiction’ and DSM-5 use disorder and
ICD-11 dependence (kappa 0.63 and 0.79, respectively). None of the classification systems was
shown to have excellent concordance with the definition of ‘Addiction’

Table 2 here

Measures of concordance between the individual criteria for ’Addiction’ and corresponding criteria
within each of the classification systems are presented in Table 3. Impaired control was the most
decisive criterion for ‘Addiction’ (PPV 1.00, NPV 0.95). The remaining three criteria showed lower
8

specificity values and much lower bias-adjusted kappas (see Table 3). Amongst the other
classification systems, given that each comprise polythetic symptom sets, there was only fair-tomoderate concordance between ‘Addiction’ criteria and DSM-IV and ICD-10 dependence, and DSM-5
use disorder. There was substantial concordance with impaired control and ICD-11 dependence
(kappa 0.72), but only slight-to-fair concordance amongst the remaining three criteria.

Table 3 here

Clinical and socio-demographic characteristics of the cohort who meet criteria for ‘addiction’, DSM-5
‘use disorder’ and ICD-11 ‘dependence’ are presented in Table 4. Only data for ‘Addiction’, use
disorder according to DSM-5 and dependence according to ICD-11 are presented. See Appendix B
(available online as Supplemental Digital Content at http://links.lww.com/PAIN/A251) for results on
dependence according to DSM-IV and ICD-10. Participants who met criteria for ‘Addiction’, compared
with those who met no diagnostic criteria for problematic use (DSM-IV, ICD-10, ICD-11 dependence
and DSM-5 use disorder), were more likely to be male, younger, less likely to be in a married or
defacto relationship, more likely to report more mental health problems, substance use histories,,,
greater patient-centred problems, more aberrant or non-adherent medication behaviours associated
with their opioid use, and a higher OME (Table 4, column E).

No differences were identified between those who did not meet criteria for any dependence/use
disorder (n=1043) and those who met criteria for ‘Addiction’ only (i.e. did not meet criteria for any
other classification of ‘dependence’ or ‘opioid use disorder’ n=51, comparison not shown in Table 4).

Compared with those meeting criteria for DSM-5 ‘opioid use disorder’ (n=202), participants who met
criteria for ‘addiction’ only (i.e. those who met criteria for ‘Addiction’ and not DSM-5, n=202) (Table
4, column F), referred to as the ‘Addiction’ only group, were significantly less likely to report having
engaged in non-adherent or aberrant behaviours in the preceding three months, less likely to report
problems or concerns with their opioid use, less likely to suffer mental health problems or to have
seen a mental health professional, or to have ever been in substance use treatment, and reported
fewer side effects, pain interference, poor pain self-efficacy scores. Further, the ‘Addiction’ only
group was also older and less likely to be unemployed, when compared with those who met criteria
for opioid use disorder according to DSM-5.
9

Compared with those who met criteria for ICD-11 ‘opioid dependence’ (n=213, Table 4, column G),
the ‘Addiction’ only group (i.e. those who met criteria for ‘Addiction’ only and not ICD-11
dependence, n=69) was significantly less likely to report aberrant behaviours, problems and concerns
with their opioid use, but had more mental health problems and were more likely to have ever seen
a health professional. They were also more likely to be older, in a married/defacto relationship and
less likely to be unemployed or have completed year 10 of school education.

Table 4 here

Discussion
There have been difficulties in determining rates of addiction/dependence in people prescribed
opioids for pain, arising out of a lack of consistency in terminology and measures used [36]. This is
the first study comparing pain medicine criteria for ‘Addiction’ with standard diagnostic criteria for
opioid use disorder in people prescribed opioids for CNCP. In this cohort, over the previous 12
months, 23.9% met criteria for ‘Addiction’, 18.8% for ICD-11 dependence, 17.8% for DSM-5
pharmaceutical opioid use disorder, and similar proportions met criteria for DSM-IV and ICD-10
pharmaceutical opioid dependence (9.4% and 8.4%, respectively). There was moderate concordance
between classifications for ‘Addiction’ and DSM-IV, ‘Addiction’ and ICD-10 dependence and
substantial concordance between ‘Addiction’ and DSM-5 use disorder and ‘Addiction’ and ICD-11
dependence. The current study highlights the importance of empirically testing the competing
definitions of opioid dependence and addiction.

Those who met ‘Addiction’ criteria were significantly more likely than those who did not meet
criteria for a disorder in any of the classification systems to have greater pain severity, more
interference from their pain and to have engaged in non-adherent behaviours. They also reported
more problems and concerns with their opioid medication use, had more mental health issues and a
greater substance use history.

At face-value therefore, the pain medicine concept of ‘Addiction’ seems to have high sensitivity in
identifying people with a range of behaviours or traits often associated with opioid dependence (i.e.,
substance use histories and non-adherent behaviours). However, comparisons of those who met
10

criteria for ‘Addiction’ only with those who met criteria for ICD-11 and DSM-5 showed that the
‘Addiction only’ group were less likely to engage in aberrant behaviours or to have problems with
their use and had lower rates of psychological distress, and substance use histories. This suggests
that the addiction definition is capturing a broader group, including some patients who may be
showing fewer problem behaviours, than those captured by existing diagnostic criteria (i.e. ICD11,
DSM-5). Finally, there were no differences between the people who were identified only by the
‘Addiction’ concept (and not by any of the other classification systems) and people who did not meet
criteria for any of the classification systems.

There are potential clinical implications of the lower threshold for an ‘Addiction’ diagnosis compared
with other dependence classification systems. It may be argued that the broader ‘addiction’
diagnosis may help target clinical strategies such as closer monitoring, safer prescribing and
dispensing practices and a greater emphasis upon non-opioid interventions. However, a definition
that is too broad may mean that some people who are not experiencing (and may never develop)
problematic opioid use may be stigmatised with a label of ‘Addiction’, and may be subjected to
unnecessary or even potentially counter-therapeutic interventions and/or changes to their treatment
plans. It is important in CNCP treatment to balance the need for effective pain relief with strategies
that aim to reduce problematic opioid use.

Another controversial issue in the use of traditional classification systems in pain medicine is whether
or not tolerance and withdrawal criteria should be included. In the current sample, 25.6% met
criteria for physical dependence (i.e. withdrawal), and 14.2% met criteria for tolerance. It has been
argued that the term dependence, according the ICD and DSM classifications, is confusing because it
includes both physical and psychological dependence [28]. Current definitions of ‘Addiction’ among
people prescribed long-term opioids for pain have not been empirically derived, although there has
been a strong clinical consensus supporting the exclusion of the features of ‘tolerance’ and
‘withdrawal’ in identifying problematic use. Physical dependence is an expected response to
prolonged exposure to opioids, and where a patient is prescribed opioids for a period of time, they
may experience withdrawal symptoms when they cease. Psychological dependence, as used in the
DSM and ICD [28] encompasses a broader behavioural syndrome, see (Table 1). The DSM-5 ‘opioid
use disorder’ classification attempted to address this issue by conditionally excluding tolerance and
physical dependence criteria in patients who used opioid medications ‘solely as prescribed’, and
these criteria were used in the current study.
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The development of the ‘addiction’ classification in pain medicine arose out of a concern that too
many individuals may be inappropriately diagnosed as ‘dependent’ according to the then DSM-IV or
ICD-10, given theinclusion of withdrawal and tolerance in those diagnostic systems (Ballantyne et al).
It is of interest that while our study found ‘substantial’ concordance between ‘Addiction’ and DSM-5
use disorder and between ‘addiction’ and ICD-11 dependence, concordance was far greater for the
latter. In a previous paper [11], we found that DSM-5 had low concordance compared with other
classifications (i.e. ICD-11, ICD-10, and DSM-IV). Criticisms of the DSM-5 suggest that the broader use
of the term opioid use disorder, which encompasses both dependence and abuse criteria, does not
equate to ‘dependence’. It is unclear which particular patient group the DSM-5 now describes, but it
appears to be different from those identified by ICD-10, by ICD-11, by DSM-IV dependence and by
the pain medicine concept of ‘Addiction’.

Of importance, the ICD and DSM classification systems were not designed specifically to address
pharmaceutical drug use in patients using medications under medical supervision. The salience of
concepts such as ‘taking a substance in larger amounts or for longer than you intend to’, ‘wanting to
cut down’, or ‘persistent use despite harms’ are yet to be well understood from the perspective of
the pain patient. This is especially challenging where medications have positives as well as negatives
in the context of medical treatment, meaning motivations to continue or to cease medication may be
unrelated to the construct of dependence, and is an important area for further work. Many such
behaviours or cognitions (desire to cut down, prolonged use, use despite harms such as side effects)
occur in patients taking medications for chronic conditions that are not CNS active, and hence may
not necessarily signify dependence or addiction. This highlights that the current classification
systems for dependence have been historically developed for substances such as alcohol and illicit
drugs. This paper examines the best definitions available, but over time diagnostic criteria may be
refined to better capture problems with medications used in a prescribed context.

Strengths and limitationsThis study used a large, national community sample of people prescribed opioids for CNCP to
compare the performance of different diagnostic criteria. However, there is the potential that we did
not succeed in recruiting a representative sample of people prescribed opioids for chronic pain. To
investigate this possibility, additional data were collected from a random sample of pharmacies
(n=71) on the characteristics of all their opioid customers seen during the six week recruitment
12

window. This revealed reassuring similarities with our sample. Among the total number of customers
recorded as purchasing opioids in these pharmacies, 52% were female (vs 55% in the POINT cohort);
and 7% were 18-34 years, 55% 35-64 years and 38% 65+ years (vs. 5%, 62% and 33% respectively, in
the POINT cohort). Two thirds (63%) were prescribed oxycodone (vs. 62% in the POINT cohort),
16.5% prescribed morphine (vs. 15% in the POINT cohort), and 24% prescribed buprenorphine
patches (vs. 21% in the POINT cohort).

A further strength herein was that we measured medication nonadherence, unlike other studies that
have examined the DSM-5 in people prescribed opioids for CNCP [4]. We were therefore able to
determine which patients were using ‘solely as prescribed’ and so could apply the conditional
exclusion of tolerance and withdrawal appropriately.

A limitation is the potential bias by reliance on self-report data. For instance, information on chronic
medical illnesses and mental health problems were not verified through patient records, but the
rates of pain conditions and findings were similar to those in previous research [5; 27]. Yet, all
participants were informed that their responses would be de-identified and confidential, an
assurance found to enhance the validity of self-reported substance use [10]. It is important to note
that the current study was cross-sectional and future prospective studies, based on community
samples, are necessary to determine which definitions of ‘Addiction’/dependence are the most
useful in identifying patients who encounter problems with their pharmaceutical opioid use. Finally,
the definitions examined in this paper are based on information collected in an interview, rather than
a diagnosis by a clinician; however, the CIDI has been found to be a reliable and valid method of
diagnosing alcohol and substance use disorders [34]
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Conclusion
Although our study provides some empirical support for what has previously been based on clinical
consensus, the ‘addiction’ concept used in pain medicine is broad and encompasses patients that
may not be at high-risk of problematic opioid use. Even after applying conditional exclusion of
tolerance and withdrawal, the DSM-5 pharmaceutical use disorder classification appears to capture a
different patient group from those of other diagnostic systems. Patients identified by ICD-11 opioid
dependence criteria were nearly all encompassed within the concept of ‘addiction’. ICD-11 opioid
dependence criteria seem to be the most promising in identifying those patients with CNCP who are
experiencing significant problems in use, to inform their ongoing treatment planning.
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Fig 1: Past 12 month diagnosis of addiction, ICD-11 and DSM-5
A total – Addiction (n=271, 23.9% of the total sample)
B total – DSM-5 use disorder (n=202, 17.8% of the total sample)
C total – ICD-11 (n=213, 18.8%)
A only – (n=51)
B only – (n=29)
C only – (n=5)
AB – Addiction/DSM-5 (n=167)
AC – Addiction/ICD-11 (n=201)
ABC – Addiction/DSM-5/ICD-11 (n=148)
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Table 1: Definitions and their operationalisation and prevalence in the POINT cohort
Term

Definition

Operationalisation

Addiction

It is characterized by behaviours that include one or more of the following: impaired control over drug use, compulsive
use, continued use despite harm, and craving.

Physical
dependence
Tolerance

A state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt
cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.
A state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the
drug's effects over time
1. Tolerance, as defined by either of the following:
(a) need for markedly increased amounts of the drug to achieve intoxication or desired effect.
(b) markedly diminished effect with continued use of the same amount of the drug.
2. Withdrawal, as manifested by either of the following:
(a) the characteristic withdrawal syndrome for the drug
(b) the same (or a closely related) substance is taken to relieve or avoid withdrawal symptoms.
3. The drug is often taken in larger amounts or over a longer period than was intended.
4. There is a persistent desire or unsuccessful efforts to cut down or control drug use
5. A great deal of time is spent in activities necessary to obtain the drug (e.g., visiting multiple doctors or driving long
distances), to use the drug, or to recover from its effects
6 Important social, occupational, or recreational activities are given up or reduced because of drug use.
7. The drug use is continued despite knowledge of having a persistent or recurrent physical or psychological problem
1. Taking the opioid in larger amounts and for longer than intended
2. Wanting to cut down or quit but not being able to do it
3. Spending a lot of time getting, using, or recovering from use of the substance
4. Cravings and urges to use the substance
5. Not managing to do what you should at work, home or school, because of substance use
6. Continuing to use, even when it causes problems in relationships
7. Giving up important social, occupational or recreational activities because of substance use
8. Using substances again and again, even when it puts the you in danger
9. Continuing to use, even when the you know you have a physical or psychological problem that could have been
caused or made worse by the substance
10. Needing more of the substance to get the effect you want (tolerance)
11. Development of withdrawal symptoms, which can be relieved by taking more of the substance.
1. Strong desire or sense of compulsion to take the drug.
2. Impaired capacity to control drug-taking behaviour in terms of its onset, termination, or levels of use, as evidenced by;
the drug being often taken in larger amounts or over a longer period than intended; or by a persistent desire or
unsuccessful efforts to reduce or control drug use.
3. A physiological withdrawal state when drug use is reduced or ceased, as evidenced by the characteristic withdrawal
syndrome for the drug, or by use of the same (or closely related) substance with the intention of relieving or avoiding
withdrawal symptoms.
4. Evidence of tolerance to the effects of the drug, such that there is a need for significantly increased amounts of the
drug to achieve intoxication or the desired effect, or a markedly diminished effect with continued use of the same
amount of the drug.
5. Preoccupation with drug use, as manifested by alternative pleasures or interests being given up or reduced because of
drug use, or a great deal of time being spent in activities necessary to obtain, take, or recover from the effects of the
drug.
6. Persistent drug use despite clear evidence of harmful consequences , as evidenced by continued use when the
individual is actually aware, or may be expected to be aware, of the nature and extent of the harm.
7. The drug use is continued despite knowledge of having a persistent or recurrent physical or psychological problem
that is likely to have been caused or exacerbated by the drug

At least one of the following (from CIDI):
impaired control over drug use, compulsive use,
continued use despite harm, and craving
Withdrawal (CIDI)

25.6 (23.1-28.2)

Tolerance (CIDI)

14.2 (12.3-16.4)

At least three in the same 12 month period

8.5 (7.0-10.2)

At least 2 of the 11 in the same 12 month period,
applying conditional exclusions to the features of
tolerance and withdrawal where relevant.

17.8 (15.7-20.2)

DSM-IV
dependence

DSM-5
disorder

use

ICD-10
dependence

•
•

Prevalence
(%,
95%CI)
23.9 (21.5-26.5)

For people using medications, as prescribed,
the tolerance and withdrawal criteria are
not included.
For people in the POINT sample, who
endorsed non-adherent behaviours such as
injection, tampering, doctor shopping, or
diversion of opioids, tolerance and
withdrawal were included

Three or more symptoms in the same 12 month
period

9.4 (7.8-11.2)

ICD-11
dependence

1. Impaired control over substance use: craving, used in larger amounts, for longer, or attempts to cut down
Essential features comprise of two of the three 18.8 (16.6-21.2)
2. Substance use is a priority in life: time spent using and recovering, other activities reduced due to use
criteria
3. Physiological features: tolerance, withdrawal or use to avoid withdrawal
The DSM-IV criteria for substance abuse and substance dependence have been combined into a single substance use disorder specific to each substance of abuse within a new "addictions and related disorders"
category. Each substance use disorder is divided into mild, moderate, and severe subtypes. Whereas DSM-IV substance abuse diagnostic criteria required only 1 symptom, a DSM-5 diagnosis even for just mild
substance use disorder now requires at least 2.

Table 2: Concordance between different measures of problematic use in the POINT cohort
‘Addiction’
(n=271)
No
Yes
(n=861)
(n=271)
‘Addiction’
No
Yes

DSM-IV dependence
(n=96)
No
Yes
(n=1037)
(n=96)
Kappa 0.46
83.1
0.00
16.9
100

Kappa 0.46
DSM-IV dependence
No
Yes
DSM-5 use disorder
No
Yes
ICD-10 dependence
No
Yes
ICD-11 dependence
No
Yes

100
0.0

64.6
35.4
Kappa 0.63
95.9
38.4
4.1
61.6
Kappa 0.48
99.8
61.6
0.2
38.4
Kappa 0.79
98.7
25.5
1.3
74.5

DSM-5 use disorder
(n=202)
No
Yes
(n=931)
(n=202)
Kappa 0.63
88.8
17.3
11.2
82.7
Kappa 0.55
99.3
0.7

Kappa 0.55
89.1
7.3
10.9
92.7
Kappa 0.88
98.5
6.3
1.5
93.8
Kappa 0.57
88.7
0.0
11.3
100.0

55.9
44.1

Kappa 0.58
99.0
52.0
1.0
48.0
Kappa 0.69
93.8
23.3
6.2
76.7

ICD-10 dependence
(n=106)
No
Yes
(n=1026)
(n=106)
Kappa 0.48
83.7
1.9
16.3
98.1
Kappa 0.88

ICD-11 dependence
(n=213)
No
Yes
(n=921)
(n=213)
Kappa 0.79
92.5
5.2
7.5
94.8
Kappa 0.57

99.4
15.1
0.6
84.9
Kappa 0.58
89.8
8.5
10.2
91.5

100
54.9
0.0
45.1
Kappa 0.69
94.9
27.2
5.1
72.8
Kappa 0.62
100
50.2
0
49.8

Kappa 0.62
89.6
0.0
10.4
100.0

Table 3: Concordance between each ‘Addiction’ criteria and different measures of problematic use in the POINT cohort
Sensitivity
(% true positive /
total positive)
Impaired control

Compulsive use

Continued use despite
harm

Craving

Addiction
DSM-IV dependence
DSM-5 opioid use disorder
ICD-10 opioid dependence
ICD-11
Addiction
DSM-IV dependence
DSM-5 opioid use disorder
ICD-10 opioid dependence
ICD-11
Addiction

81.9
84.4
67.3
80.2
78.9
30.6
58.3
36.1
54.7
35.2
19.9

Specificity
(% true
negative/total
negative)
100
86.4
90.8
86.6
94.1
100
97.4
98.9
97.6
99.1
100

DSM-IV dependence
DSM-5 opioid use disorder
ICD-10 opioid dependence
ICD-11
Addiction
DSM-IV dependence
DSM-5 opioid use disorder
ICD-10 opioid dependence
ICD-11

44.8
25.2
40.6
23.5
17.0
24.4
20.3
36.8
19.7

98.9
99.7
98.9
99.6
100
98.7
99.5
99.3
99.6

Positive predictive
value

Negative predictive
value

Bias adjusted
kappa

1.00
0.36
0.61
0.38
0.76
1.00
0.67
0.88
0.70
0.90
1.00

0.95
0.98
0.93
0.98
0.95
0.82
0.96
0.88
0.95
0.87
0.80

0.87
0.43
0.56
0.44
0.72
0.37
0.59
0.44
0.58
0.43
0.22

0.80
0.94
0.80
0.93
1.00
0.72
0.89
0.85
0.91

0.95
0.86
0.94
0.85
0.79
0.94
0.85
0.94
0.84

0.54
0.32
0.50
0.29
0.17
0.43
0.25
0.48
0.24

Table 4: Opioid use and health service utilisation of the POINT cohort according to problematic use definitions (n=1134)
A. Do not meet
criteria for any
problem use
n=823

B. “Addiction”
n=271

C. DSM-5 opioid
use disorder
n=202

D. ICD-11
dependence
n=213

E. A (ref) vs B
(271 vs 823)
OR (95%CI)

F. Addiction only vs
DSM-5 (C.) (ref)
(104 vs 202)
OR (95%CI)

G. Addiction only
VS ICD-11 (D.)(ref)
(69 vs 213)
OR (95%CI)

History of opioid use
Years of prescribed opioid use (MDN IQR)
7 (4-13)
6 (4-14)
6 (4-12)
6 (4-12)
99.7 (0.98-1.01)
1.03 (1.00-1.06)*
1.02 (0.99-1.05)
Years since first symptom of problems related to prescribed
5 (3-11.5)
4 (3-8)
5 (3-8)
4 (3-7.5)
0.97 (0.94-1.00)*
1.02 (0.97-1.07)
1.03 (0.97-1.09)
opioids (MDN IQR)
Current OME (MDN, IQR)#
65.0 (34.2-150.0)
104.2 (45.0-178.7)
111 (50-180)
111 (47.4-180)
1.00 (1.00-1.00)*
1.00 (1.00-1.00)
1.00 (1.00-1.00)
Past 3 month non-adherence score (ORBIT) (MDN, IQR)
0 (0-1)
1 (0-2)
1 (0-3)
1 (02)
1.27 (1.18-1.38)***
0.78 (0.68-0.90)**
0.86 (0.74-1.00)*
Problems with prescribed opioids (PODS) score (MDN, IQR)
3 (0-8)
9 (2-19)
14 (5-21)
11 (4-21)
1.09 (1.07-1.10)***
0.91 (0.89-0.94)***
0.92 (0.90-0.96)***
Concerns with prescribed opioids (PODS) score (MDN, IQR)
4 (0-8)
12 (8-16)
12 (8-20)
12 (8-20)
1.19 (1.16-1.22)***
0.89 (0.85-0.93)***
0.87 (0.82-0.91)***
% opioid side effects (PADT)
75.3 (72.3-78.2)
81.9 (76.8-86.1)
86.6 (81.2-90.7)
83.6 (77.9-88.0)
1.48 (1.05-2.10)*
0.44 (0.24-0.80)**
0.65 (0.33-1.27)
Service utilisation
% more than one opioid prescriber+
14.6 (12.3-17.2)
19.9 (15.6-25.1)
19.3 (14.4-25.4)
20.2 (15.3-26.2)
1.46 (1.02-2.08)*
0.87 (0.47-1.62)
0.78 (0.36-1.55)
% ever mental health professional+
41.6 (38.2-44.9)
61.3 (55.3-66.9)
64.9 (58.0-71.2)
64.3 (57.6-70.5)
2.22 (1.68-2.94)***
0.59 (0.36-0.95)*
0.57 (0.33-0.99)*
Clinical correlates
Median pain severity (SD)
5.0 (1.8)
5.3 (1.8)
5.4 (1.8)
5.3 (1.8)
1.11 (1.02-1.19)*
0.90 (0.79-1.03)
1.01 (0.87-1.18)
Median pain interference (SD)
5.2 (2.3)
6.0 (2.3)
6.4 (2.2)
6.2 (2.3)
1.18 (1.11-1.26)***
0.80 (0.72-0.89)***
0.90 (0.80-1.01)
% low pain self-efficacy (<30 PSEQ)
37.5 (34.2-40.8)
49.8 (43.9-55.8)
57.9 (50.9-64.6)
52.6 (45.8-59.3)
1.66 (1.26-2.18)***
0.29 (0.18-0.48)***
0.65 (0.38-1.13)
% poor physical functioning (<30 SF-12)+
72.9 (69.5-76.1)
63.7 (57.1-69.8)
64.6 (56.8-71.7)
62.9 (55.4-69.9)
0.65 (0.47-0.90)**
1.00 (0.58-1.70)
1.15 (0.62-2.12)
% Current generalised anxiety disorder
11.6 (9.6-14.0)
28.0 (23.0-33.7)
38.6 (32.1-45.6)
32.9 (26.8-39.5)
2.97 (2.12-4.18)***
0.23 (0.12-0.43)***
0.31 (0.14-0.65)**
% Current moderate to severe depression
30.6 (27.5-33.8)
56.8 (50.8-62.6)
67.3 (60.5-73.5)
60.6 (53.8-67.0)
2.99 (2.25-3.96)***
0.28 (0.16-0.46)***
0.47 (0.27-0.82)**
% post-traumatic stress disorder+
11.3 (9.3-13.7)
24.9 (19.2-29.5)
25.7 (20.1-32.3)
26.3 (20.8-32.7)
2.49 (1.75-3.54)***
0.60 (0.33-1.10)
0.53 (0.26-1.08)
% lifetime alcohol use disorder+
28.3 (25.3-31.4)
39.5 (33.8-45.5)
39.1 (32.6-46.0)
41.3 (34.8-48.1)
1.69 (1.27-2.26)***
0.97 (0.60-1.58)
0.86 (0.49-1.50)
% lifetime illicit drug use disorder**+
11.3 (9.3-16.7)
22.1 (17.6-27.5)
26.2 (20.6-32.8)
25.8 (20.3-32.2)
2.23 (1.56-3.20)***
0.55 (0.30-1.01)
0.49 (0.23-1.02)
% family history of problematic use+
3.8 (2.7-5.5)
8.9 (5.6-14.0)
10.8 (6.7-17.0)
9.9 (6.5-14.7)
2.29 (1.32-3.99)**
0.46 (0.15-1.42)
0.27 (0.06-1.20)
% ever treatment for SUD +
7.8 (6.1-9.8)
19.2 (14.9-24.4)
24.8 (19.2-31.2)
22.1 (17.0-28.2)
2.9 (1.9-4.2)***
0.29 (0.14-0.61)**
0.46 (0.21-1.04)
% childhood maltreatment+
48.6 (45.2-52.0)
61.3 (55.3-66.9)
62.9 (55.9-69.3)
65.7 (59.0-71.8)
1.67 (1.26-2.21)***
0.81 (0.50-1.30)
0.60 (0.35-1.05)
Demographic variables
% male+
39.2 (36.0-42.6)
52.0 (46.0-58.0)
56.9 (50.0-63.6)
53.1 (46.3-59.7)
0.60 (0.45-0.79)***
1.54 (0.96-2.48)
1.10 (0.64-1.89)
Median age (IQR)
62 (54-71)
56 (46-65)
53 (43-60)
54 (45-62)
0.96 (0.95-0.97)***
1.06 (1.04-1.09)***
1.04 (1.02-1.07)**
% completed year 10 +
81.0 (78.1-83.5)
85.2 (80.5-89.0)
88.6 (83.4-92.3)
89.2 (84.2-92.7)
1.36 (0.93-1.98)
0.48 (0.25-0.91)*
0.34 (0.17-0.68)**
% Income below AUD 400 +
60.0 (56.6-63.3)
54.2 (48.2-60.1)
50.5 (43.6-57.4)
54.5 (47.7-61.1)
0.79 (0.60-1.04)
1.39 (0.86-2.42)
1.03 (0.59-1.77)
% unemployed/not in labour force
39.5 (36.2-42.9)
49.8 (43.9-55.8)
55.4 (48.5-62.2)
54.0 (47.2-60.6)
1.51 (1.15-2.00)**
0.54 (0.34-0.88)*
0.55 (0.31-0.95)*
% married/defacto +
55.2 (51.7-58.5)
49.4 (43.5-55.4)
46.0 (39.2-53.0)
46.0 (39.4-52.8)
0.79 (0.60-1.05)
1.42 (0.88-2.29)
1.94 (1.11-3.39)*
** includes meth/amphetamine, cannabis, cocaine, ecstasy, hallucinogenics, heroin. + from baseline interview + Did not meet criteria for DSM-IV ICD-10, ICD-11 dependence and DSM-5 opioid use disorder, # based on
sample of 1,035. OME-Oral morphine equivalents, mg/day
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